Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19)

Pourya Gholizadeh,1,2 Rohollah Safari,3 Parham Marofi,4 Elham Zeinalzadeh,4 Pasquale Pagliano,5 Khudaverdi Ganbarov,6 Silvano Esposito,5 Ehsaneh Khodadadi,7 Mehdi Yousefi,8 Hossein Samadi Kafil7 1Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; 2Biotechnology Research...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gholizadeh P, Safari R, Marofi P, Zeinalzadeh E, Pagliano P, Ganbarov K, Esposito S, Khodadadi E, Yousefi M, Samadi Kafil H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	sars-cov-2 covid-19 hepatic injury liver enzymes aminotransferases. Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/415b9e446def41ada92ddc7dfdb65a6d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:415b9e446def41ada92ddc7dfdb65a6d
record_format	dspace
spelling	oai:doaj.org-article:415b9e446def41ada92ddc7dfdb65a6d2021-12-02T08:33:47ZAlteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19)1178-7031https://doaj.org/article/415b9e446def41ada92ddc7dfdb65a6d2020-07-01T00:00:00Zhttps://www.dovepress.com/alteration-of-liver-biomarkers-in-patients-with-sars-cov-2-covid-19-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Pourya Gholizadeh,1,2 Rohollah Safari,3 Parham Marofi,4 Elham Zeinalzadeh,4 Pasquale Pagliano,5 Khudaverdi Ganbarov,6 Silvano Esposito,5 Ehsaneh Khodadadi,7 Mehdi Yousefi,8 Hossein Samadi Kafil7 1Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; 2Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 3Department of Microbiology, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran; 4Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 5Department of Medicine, University of Salerno, Salerno, Italy; 6Department of Microbiology, Baku State University, Baku, Republic of Azerbaijan; 7Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 8Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, IranCorrespondence: Hossein Samadi Kafil Tel +98-9127184735Fax +98-4133364661Email Kafilhs@tbzmed.ac.irIntroduction: Coronavirus disease 2019 (COVID-19) emerged in China and spread worldwide. In this study, we assessed the characteristics of markers of the liver in patients with COVID-19 to provide new insights in improving clinical treatment.Patients and Methods: We recruited 279 patients who confirmed COVID-19 and the data of liver biomarkers and complete blood count of patients were defined as the day onset when the patients admitted to the hospital.Results: The average of LDH value was 621.29 U/L in all patients with COVID-19, and CPK was 286.90 U/L. The average AST was 44.03 U/L in all patients, and ALT was 31.14 U/L. The AST/ALT ratio was 1.64 in all patients. The measurement of CRP was increased by 79.93% in all patients. Average ALT and AST values of patients with elevated ALT were significantly increased in comparison to patients with normal ALT (P-value = 0.001), while AST/ALT ratio was significantly decreased compared to patients with normal ALT (P-value= 0.014). In addition, the average LDH of patients with elevated ALT was significantly increased compared to patients with normal ALT (P-value = 0.014).Conclusion: Hepatic injury and abnormal liver enzymes related to COVID-19 infection is an acute non-specific inflammation alteration.Keywords: SARS-CoV-2, COVID-19, hepatic injury, liver enzymes, aminotransferasesGholizadeh PSafari RMarofi PZeinalzadeh EPagliano PGanbarov KEsposito SKhodadadi EYousefi MSamadi Kafil HDove Medical Pressarticlesars-cov-2covid-19hepatic injuryliver enzymesaminotransferases.PathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 13, Pp 285-292 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	sars-cov-2 covid-19 hepatic injury liver enzymes aminotransferases. Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	sars-cov-2 covid-19 hepatic injury liver enzymes aminotransferases. Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Gholizadeh P Safari R Marofi P Zeinalzadeh E Pagliano P Ganbarov K Esposito S Khodadadi E Yousefi M Samadi Kafil H Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19)
description	Pourya Gholizadeh,1,2 Rohollah Safari,3 Parham Marofi,4 Elham Zeinalzadeh,4 Pasquale Pagliano,5 Khudaverdi Ganbarov,6 Silvano Esposito,5 Ehsaneh Khodadadi,7 Mehdi Yousefi,8 Hossein Samadi Kafil7 1Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; 2Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 3Department of Microbiology, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran; 4Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 5Department of Medicine, University of Salerno, Salerno, Italy; 6Department of Microbiology, Baku State University, Baku, Republic of Azerbaijan; 7Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 8Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, IranCorrespondence: Hossein Samadi Kafil Tel +98-9127184735Fax +98-4133364661Email Kafilhs@tbzmed.ac.irIntroduction: Coronavirus disease 2019 (COVID-19) emerged in China and spread worldwide. In this study, we assessed the characteristics of markers of the liver in patients with COVID-19 to provide new insights in improving clinical treatment.Patients and Methods: We recruited 279 patients who confirmed COVID-19 and the data of liver biomarkers and complete blood count of patients were defined as the day onset when the patients admitted to the hospital.Results: The average of LDH value was 621.29 U/L in all patients with COVID-19, and CPK was 286.90 U/L. The average AST was 44.03 U/L in all patients, and ALT was 31.14 U/L. The AST/ALT ratio was 1.64 in all patients. The measurement of CRP was increased by 79.93% in all patients. Average ALT and AST values of patients with elevated ALT were significantly increased in comparison to patients with normal ALT (P-value = 0.001), while AST/ALT ratio was significantly decreased compared to patients with normal ALT (P-value= 0.014). In addition, the average LDH of patients with elevated ALT was significantly increased compared to patients with normal ALT (P-value = 0.014).Conclusion: Hepatic injury and abnormal liver enzymes related to COVID-19 infection is an acute non-specific inflammation alteration.Keywords: SARS-CoV-2, COVID-19, hepatic injury, liver enzymes, aminotransferases
format	article
author	Gholizadeh P Safari R Marofi P Zeinalzadeh E Pagliano P Ganbarov K Esposito S Khodadadi E Yousefi M Samadi Kafil H
author_facet	Gholizadeh P Safari R Marofi P Zeinalzadeh E Pagliano P Ganbarov K Esposito S Khodadadi E Yousefi M Samadi Kafil H
author_sort	Gholizadeh P
title	Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19)
title_short	Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19)
title_full	Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19)
title_fullStr	Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19)
title_full_unstemmed	Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19)
title_sort	alteration of liver biomarkers in patients with sars-cov-2 (covid-19)
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/415b9e446def41ada92ddc7dfdb65a6d
work_keys_str_mv	AT gholizadehp alterationofliverbiomarkersinpatientswithsarscov2covid19 AT safarir alterationofliverbiomarkersinpatientswithsarscov2covid19 AT marofip alterationofliverbiomarkersinpatientswithsarscov2covid19 AT zeinalzadehe alterationofliverbiomarkersinpatientswithsarscov2covid19 AT paglianop alterationofliverbiomarkersinpatientswithsarscov2covid19 AT ganbarovk alterationofliverbiomarkersinpatientswithsarscov2covid19 AT espositos alterationofliverbiomarkersinpatientswithsarscov2covid19 AT khodadadie alterationofliverbiomarkersinpatientswithsarscov2covid19 AT yousefim alterationofliverbiomarkersinpatientswithsarscov2covid19 AT samadikafilh alterationofliverbiomarkersinpatientswithsarscov2covid19
_version_	1718398478700249088

Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19)

Ejemplares similares